Open AccessRiociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT‐1/‐2 studies
Author(s) -
CartinCeba Rodrigo,
Halank Michael,
Ghofrani HosseinArdeschir,
Humbert Marc,
Mattson John,
Fritsch Arno,
Krowka Michael
Publication year - 2018
Publication title -
pulmonary circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.791
H-Index - 40
ISSN - 2045-8940
DOI - 10.1177/2045894018769305
Subject(s) - riociguat , portopulmonary hypertension , medicine , placebo , subgroup analysis , randomized controlled trial , open label , portal hypertension , cardiology , pulmonary hypertension , chronic thromboembolic pulmonary hypertension , cirrhosis , alternative medicine , pathology , meta analysis
In patients with portopulmonary hypertension (n = 13) included in the 12‐week randomized placebo‐controlled PATENT‐1 trial, riociguat was well tolerated and improved 6‐min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open‐label extension, PATENT‐2.